共 50 条
- [2] Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Hormone-sensitive Prostate Cancer [J]. EUROPEAN UROLOGY, 2022, 82 (05) : E135 - E136
- [3] Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer [J]. UROLOGIE, 2023, 62 (04): : 360 - 368
- [4] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
- [6] Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer [J]. UROLOGIE, 2023, 62 (04): : 354 - 359
- [7] Current status of androgen deprivation therapy in hormone-sensitive prostate cancer [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (03): : 247 - 257
- [9] Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy [J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1519 - 1520